Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 17, 2009, Pages 6213-6217

  Jeong, Hee Chun ^a   Park, No Joong ^a   Chae, Chong Hak ^a   Musilek, Kamil ^b   Kassa, Jiri ^b   Kuca, Kamil ^b,c   Jung, Young Sik ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; Fluorinated pyridinium oxime; Organophosphorus agents; Oxime reactivators

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; ACETYLCHOLINESTERASE; FLUORINE DERIVATIVE; OXIME DERIVATIVE; PARAOXON; PRALIDOXIME; PROPRANOLOL; PYRIDINIUM DERIVATIVE; WARFARIN;

ANIMAL TISSUE; ARTICLE; ARTIFICIAL MEMBRANE; CARBON NUCLEAR MAGNETIC RESONANCE; CATTLE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME REACTIVATION; ERYTHROCYTE; HOUSE FLY; MEMBRANE PERMEABILITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; ERYTHROCYTES; HALOGENATION; HUMANS; OXIMES; PARAOXON; PYRIDINIUM COMPOUNDS;

EID: 68649128585     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.07.043     Document Type: Article

References (16)

1. Taylor, P. Anticholinergic agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G.; Limbird, L. E.; Gilman, A. G., Eds.; McGraw Hill: New York, 1996; pp 175-191.
2. Wilson I.B. J. Biol. Chem. 190 (1951) 111
3. Bajgar J., Fusek J., Kuca K., Bartosova L., and Jun D. Mini Rev. Med. Chem. 7 (2007) 461
4. Lorke D.E., Kalasz H., Petroianu G.A., and Tekes K. Curr. Med. Chem. 15 (2008) 743
5. In: Bohm H.J., and Schneider G. (Eds). Protein-Ligand Interactions (2003), Wiley-VCH, Weinheim
6. Wildman S.A., and Crippen G.M. J. Chem. Inf. Comput. Sci. 39 (1999) 868
7. Jeong H.C., Kang N.S., Park N.J., Yum E.K., and Jung Y.S. Bioorg. Med. Chem. Lett. 19 (2009) 1214
8. Musilek K., Jun D., Cabal J., Kassa J., Gunn-Moore F., and Kuca K. J. Med. Chem. 50 (2007) 5514
9. Kim T.H., Kuca K., Jun D., and Jung Y.S. Bioorg. Med. Chem. Lett. 15 (2005) 2914
10. Oh K.A., Yang G.Y., Jun D., Kuca K., and Jung Y.S. Bioorg. Med. Chem. Lett. 16 (2006) 2914
11. Yang G.Y., Oh K.A., Park N.J., and Jung Y.S. Bioorg. Med. Chem. 15 (2007) 7704
12. Oh K.A., Park N.J., Park N.S., Kuca K., Jun D., and Jung Y.S. Chem-Bio. Int. 175 (2008) 365
13. 12AChE Inhibition and reactivation: DFP and paraoxon were used as organophosphorus inhibitors and the AChE reactivating capability of 2-PAM and HI-6 were examined against OP-inhibited HF and RBC AChE, respectively. To remove excess inhibitor, reaction mixture was partitioned with twofold volume of hexane, and then the aqueous phase was separated by centrifugation, and incubated with reactivators. The filtrate from Sephadex-G50 (BioRad) micro-column was used to measure the AChE activity.AChE Reactivation with newly synthesized oxime compounds: The inhibited AChE separated from hexane partitioning was reacted with 5 mM of each oxime compound for 30 min for DFP-inhibited AChE and for 1 h for paraoxon-inhibited AChE, respectively.
14. Avdeef A. Exp. Opin. Drug Metab. Toxicol. 1 (2005) 325
15. Wohnsland F., and Faller B. J. Med. Chem. 44 (2001) 923
16. Ellman G.L., Courtney K.D., Andres V., and Featherstone B.C. Biochem. Pharmacol. 7 (1961) 88